Syndax Pharmaceuticals, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 13G, Stake over 5%, passiveAug 7 →InsidersNo open-market buys. 3 insiders sold $2.0M, 2 of 8 sales on a 10b5-1 plan.→HoldersBlackRock 10.1%Kynam 9.0%Goldman Sachs 6.6%→Financing →PeersClosest companies: CHRS, VSTM, SMMT→
From the filings
Figures
- Revenue
- $252.3Mlast 12 months
- Net income
- −$220.7Mlast 12 months
- Operating cash flow
- −$278.2Mlast 12 months
- Cash and equivalents
- $336.5Mat the last balance sheet
- Total debt
- $344.0Mat the last balance sheet
- Shares outstanding
- 89.2M shareson issue